









Markets
/
Stocks
/
nasdaq-srts
/

Sensus Healthcare Inc

SRTS

3.110USD

-0.030-0.96%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

51.13MMarket Cap

LossP/E TTM



Sensus Healthcare Inc

3.110

-0.030-0.96%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

109 / 207

Overall Ranking

247 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

8.000

Target Price

+154.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.

Growing

The company is in a growing phase, with the latest annual income totaling USD 41.81M.

Undervalued

The company’s latest PE is -59.85, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 7.09M shares, decreasing 22.77% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 740.02K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.03.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.07, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 7.32M, representing a year-over-year decrease of 20.82%, while its net profit experienced a year-over-year decrease of 164.33%.

Score

Industry at a Glance

Previous score

7.07

Change



Financials

9.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.05

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.12

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.20

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -60.43, which is -129.42% below the recent high of 17.78 and 111.67% above the recent low of 7.05.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 109/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Sensus Healthcare Inc is 8.00, with a high of 10.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

8.000

Target Price

+154.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Sensus Healthcare Inc

SRTS

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.55, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 3.39 and the support level at 2.99, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.55

Change

-0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.079

Neutral

RSI(14)

35.941

Neutral

STOCH(KDJ)(9,3,3)

16.859

Neutral

ATR(14)

0.100

Low Volatility

CCI(14)

-114.410

Sell

Williams %R

90.244

Oversold

TRIX(12,20)

-0.873

Sell

StochRSI(14)

64.723

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.128

Sell

MA10

3.176

Sell

MA20

3.217

Sell

MA50

3.936

Sell

MA100

4.310

Sell

MA200

5.175

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 43.13%, representing a quarter-over-quarter decrease of 0.60%. The largest institutional shareholder is The Vanguard, holding a total of 740.02K shares, representing 4.50% of shares outstanding, with 0.34% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Solot (Edwin L)

1.25M

-18.78%

Sardano (Joseph C)

1.18M

The Vanguard Group, Inc.

Star Investors

740.02K

Dimensional Fund Advisors, L.P.

541.74K

+43.10%

Pacific Ridge Capital Partners, LLC

114.50K

Acadian Asset Management LLC

470.71K

+35.28%

Renaissance Technologies LLC

Star Investors

259.63K

-39.75%

Florida State Board of Administration

67.58K

Driehaus Capital Management, LLC

86.74K

+127.19%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.12, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.